Last week, the U.S. Food and Drug Administration (FDA) finalized two important Drug Supply Chain Security Act (DSCSA)-related guidances that aim to help pharmaceutical trading partners understand their compliance obligations for packages and homogenous cases of product that are not labeled with a product identifier and that are in the distribution supply chain at the time of the effective date of the requirements of the DSCSA.
Please see full publication below for more information.